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study question: Does the sperm DNA fragmentation index (DFI) improve depending on the FSH receptor (FSHR) genotype as assessed
by the nonsynonymous polymorphisms rs6166 (p.N680S) after 3 months of recombinant FSH treatment in men with idiopathic infertility?
summary answer: FSH treatment significantly improves sperm DFI only in idiopathic infertile men with the p.N680S homozygous N
FSHR.
what is known already: FSH, fundamental for spermatogenesis, is empirically used to treat male idiopathic infertility and several
studies suggest that DFI could be a candidate predictor of response to FSH treatment, in terms of probability to conceive. Furthermore, it is
known that the FSHR single nucleotide polymorphism (SNP) rs6166 (p.N680S) influences ovarian response in women and testicular volume
in men.
study design, size and duration: A multicenter, longitudinal, prospective, open-label, two-arm clinical trial was performed. Sub-
jects enrolled were idiopathic infertile men who received 150 IU recombinant human FSH s.c. every other day for 12 weeks and were followed-up
for a further 12 weeks after FSH withdrawal. Patients were evaluated at baseline, at the end of treatment and at the end of follow-up.
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participants/materials, setting, methods: Eighty-nine men with idiopathic infertility carrier of the FSHR p.N680S homo-
zygous N or S genotype, FSH ≤ 8 IU/l and DFI .15%, were enrolled. A total of 66 patients had DFI analysis completed on at least two visits. DFI
was evaluated in one laboratory by TUNEL/PI (propidium iodide) assay coupled to flow cytometry, resolving two different fractions of sperm,
namely the ‘brighter’ and ‘dimmer’ sperm DFI fractions.
main results and the role of chance: Thirty-eight men (57.6%) werecarriers of the p.N680S homozygous N and 28 (42.4%) of
the homozygous S FSHR. Sperm concentration/number was highly heterogeneous and both groups included men ranging from severe oligozoos-
permia to normozoospermia. Total DFI was significantly lower at the end of the study in homozygous carriers of the p.N680S N versus p.N680S S
allele (P ¼ 0.008). Total DFI decreased significantly from baseline to the end of the study (P ¼ 0.021) only in carriers of the p.N680S homozygous
N polymorphism, and this decrease involved the sperm population containing vital sperm (i.e. brighter sperm) (P ¼ 0.008). The dimmer sperm
DFI fraction, including only nonvital sperm, was significantly larger in p.N680S S homozygous patients than in homozygous N men (P ¼ 0.018).
Total DFI was inversely related to total sperm number (P ¼ 0.020) and progressive sperm motility (P ¼ 0.014). When patients were further strati-
fied according to sperm concentration (normoozospermic versus oligozoospermic) or -211G.T polymorphism in the FSHB gene (rs10835638)
(homozygous G versus others), the significant improvement of sperm DFI in FSHR p.N680S homozygous N men was independent of sperm con-
centration and associated with the homozygous FSHB -211G.T homozygous G genotype.
limitations, reasons for caution: The statistical power of the study is 86.9% with alpha error 0.05. This is the first pharmaco-
genetic study suggesting that FSH treatment induces a significant improvement of total DFI in men carriers of the p.N680S homozygous N FSHR;
however, the results need to be confirmed in larger studies using a personalized FSH dosage and treatment duration.
wider implications of the findings: The evaluation of sperm DFI as a surrogate marker of sperm quality, and of the FSHR SNP
rs6166 (p.N680S), might be useful to predict the response to FSH treatment in men with idiopathic infertility.
study funding/competing interest(s): The study was supported by an unrestricted grant to M.S. and H.M.B. from Merck
Serono that provided the drug used in the study. MS received additional grants from Merck Serono and IBSA as well as honoraria from Merck
Serono. The remaining authors declare that no conflicts of interest are present.
trial registration number: EudraCT number 2010-020240-35.
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Introduction
Male factor infertility is involved in 50% of cases of couple infertility, al-
though its pathogenesis remains largely unknown (Kumar and Singh,
2015). In most cases, the treatment of male infertility relies on assisted
reproductive technology (ART), which is expensive and relatively ineffi-
cient and represents a remarkable example of gender inequity (Chansel-
Debordeaux et al., 2015). In fact, ART for male factor infertility requires
hormonal treatment of the fertile woman, who alone suffers sometimes
life-threatening side effects (Nardelli et al., 2014). Generally, ART does
not foresee pharmacological optimization of the male partner.
Spermatogenesis is a gonadotrophin-dependent process and the ad-
ministration of FSH has been used to improve sperm parameters in
men with idiopathic oligozoospermia (Acosta et al., 1991, 1992).
Several clinical trials wereconducted to evaluate the efficacyof FSH treat-
ment of the man in terms of increased pregnancy rate for the couple in
ART cycles. However, none of these studies was powered to detect sig-
nificant changes in pregnancy rate as a result of FSH therapy. Recently, a
Cochrane meta-analysis suggested that FSH therapy in men with idio-
pathic infertility and normal serum FSH concentrations may increase sig-
nificantly spontaneous pregnancy rate (13.4%), considering, however,
only four RCTs (Attia et al., 2013). We recently confirmed these
results with an extended meta-analysis of all controlled trials, demon-
strating that FSH treatment of the male improves the couples’ pregnancy
rate for their partner, both spontaneous and after ART (Santi et al.,
2015). However, the response to FSH treatment is variable and
unpredictable, mainly because the factors influencing the response
to FSH are poorly understood (Santi et al., 2015). In addition, the
pharmacodynamic effects of FSH in men are not easily measurable, so
that ‘responders’ cannot be identified beforehand.
FSH action on Sertoli cells is mediated by the FSH receptor (FSHR),
which possesses several polymorphisms demonstrated to affect recep-
tor sensitivity and expression (Casarini et al., 2014, 2015). The
Ala307Thr (rs6165) and the Ser680Asn (rs6166) polymorphisms are
well characterized in the literature, in terms of frequency and ethnic dis-
tribution (Simoni and Casarini, 2014). In women, the FSHR Ser680Asn
polymorphism (nomenclature: FSHR p.N680S) influences the response
to FSH (Perez Mayorga et al., 2000; Behre et al., 2005). In particular,
FSHR p.N680S homozygous S women require more FSH compared
with women with the FSHR p.N680S homozygous N genotype to
achieve the same level of ovarian stimulation (Behre et al., 2005). In
men, a slight influence on reproductive parameters of the FSHR
p.N680S polymorphism was recently demonstrated (Grigorova et al.,
2013).
Despite the possible FSHR genotype influence on spermatogenesis,
this effect is not easily measurable considering the wide variability in
male fertility-related parameters. Conventional semen analysis describes
only visible features of spermatozoa and does not allow any prediction of
the genetic constitution of the male gamete. The sperm DNA fragmen-
tation index (DFI) was recognized as a predictor of the probability to con-
ceive (Muratori et al., 2015a,b), and FSH treatment seemsto improve this
parameter in infertile men (Colacurci et al., 2012). The introduction and
validation of the TUNEL/propidium iodide (PI) method allowed distin-
guishing between the brighter sperm fraction (containing viable sperm)
and the dimmer fraction (where sperm are all dead) (Muratori et al.,
2008, 2015a,b). The brighter DFI fraction predicts natural conception,
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independently of age and semen parameters (Muratori et al., 2015a,b).
Therefore, DFI in the brighter and dimmer fraction represents a promis-
ing pharmacodynamic parameter of FSH action.
Overall, it appears that FSH treatment improves pregnancy rate in
couples, in which the male partner presented idiopathic infertility but
the response to FSH is variable and unpredictable. The main objective
of this study is the evaluation of whether FSH is differently effective on




A Phase IIb, multicenter, prospective, open label, one arm, clinical trial, strati-
fied according to the patient’s FSHR genotype was carried out (trial registra-
tion number: EudraCT 2010-020240-35). The centers participating in the
study were: Unit of Endocrinology, Department of Biomedical, Metabolic
and Neural Sciences, University of Modena and Reggio Emilia, Italy; Depart-
ment of Gynecology, Humanitas Fertility Center, Research Hospital,
Rozzano (Milan), Italy; Center for Reproductive Medicine and Andrology,
Martin Luther University Halle-Wittenberg, Germany; Sexual Medicine and
Andrology Unit, University of Florence, Italy; Department of Experimental
Medicine, University of Rome ‘La Sapienza’, Italy; Unit of Andrology and Re-
productive Medicine, University of Padova, Italy.
The study compared the response with the same FSH regimen in terms of
changes in sperm DFI. Only FSHR p.N680S N and S homozygous men were
included in the study. The FSHR p.N680S genotype was analyzed in one la-
boratory and the treating physician received only the information on
whether the patient was eligible for entering the trial (i.e. homozygous) but
both the physician and the patient remained blind to the genotype.
Subsequently, the response to the same FSH regimen was evaluated con-
sidering also the FSHB -211G.T genotype.
All subjects included in the study underwent a treatment phase of
12 weeks, receiving recombinant FSH therapy (follitropin alpha: Gonal-f)
150 IU s.c. every other day. The follow-up phase continued for a further
12 weeks after the end of the treatment.
Subjects
Inclusion criteria were: age 20–50 years, idiopathic male factor infertility for
at least 1 year, homozygous FSHR p.N680S N or S genotype, sperm DFI .
15%, normal serum FSH levels (≤8 IU/l), normal serum LH, testosterone,
prolactin and estradiol levels, as measured at the recruiting centers and con-
sidering the reference range of the method used in each center. A normal
ovulatory female partner was required. Exclusion criteria were azoospermia,
all known etiologies of male infertility, such as endocrine disorders, varico-
cele, cryptorchidism, infections, immunological infertility and obstructive in-
fertility, and genetic disorders causing infertility, such as chromosome
abnormalities, congenital bilateral absence of the vas deferens and microde-
letions within the AZF regions of the Y chromosome. (Esteves and Chan,
2015). Moreover, all known etiologies of female infertility in the partner
(such as tubal occlusion, endometriosis, endocrine abnormalities including
anovulation and polycystic ovaries, anatomical abnormalities, infections),
heterozygous FSHR p.N680S genotype, drug abuse, major systemic diseases
and primary testicular failure were reasons for exclusion. ART could be
planned during the study, although it was neither an inclusion nor an exclusion
criterion.
Each center involved in the study evaluated, enrolled, treated and followed
up the patients.Written informed consent was obtained fromall participants,
and the Institutional review Board approval for the study was obtained.
Methods and patient allocation
Randomization was not applicable as all men included in this study were
treated with the same dose of FSH. A blood EDTA sample for DNA analysis
was sent at room temperature to the Department of Endocrinology,
Modena, Italy for analysis of FSHR genotype. The investigators at the study
sites as well as the patients were only informed whether the patient was
homozygous for the FSHR gene at codon 680 or heterozygous. All persons
involved in analysis of the FSHR genotype were not involved in the collection
of any other study data. All persons involved in data collection as well as the
patients remained blinded up to final database closure.
Semen analysis and basal hormone determination to assess eligibility cri-
teria were performed at the study sites (WHO, 2010). A blood sample
was collected at each visit and serum was stored at 2208C at the sites
until the end of the study, when sera were shipped to the coordinating
center in Modena for hormone analysis. For DFI determination, sperm
were fixed and labeled using TUNEL at the study sites and shipped to
the Andrology Laboratory of Florence for flow cytometric analysis within
1 week from collection.
At each study visit, a serum sample was prepared and stored at 2208C
until the shipment to the Central Laboratory in Modena.
The study was independently approved by the Ethics Committee of each
participating center (File Number of the coordinating center: 114/10). Each
participant gave written informed consent.
Hormone assays
At the end of the study, serum total testosterone was measured by Chemi-
luminescent Microparticle Immunoassay (Architect, Abbott, Dundee, UK),
with inter- and intra-assay coefficients of variation (CV) of 5.2 and 5.1%, re-
spectively. Serum total estradiol was measured by Chemiluminescent Micro-
particle Immunoassay (Architect, Abbott, Longford, Ireland) with inter- and
intra-assay CV of 7.4 and 6.4%, respectively. The analytical sensitivity was
≤10 pg/ml, linearity to 1000 pg/ml. The cross-reactivity with estrone and
with 17 b-estradiol 3-sulfate was 0.7 and 0.1%, respectively. FSH and LH
were measured by Chemiluminescent Microparticle Immunoassay (Archi-
tect, Abbott, Longford, Ireland) with inter- and intra-assay CV of 4.1 and
3.1% for LH, and 4.6 and 4.2% for FSH, respectively. Inhibin B was measured
by enzyme-linked immunosorbent assay (Inhibin B Gen II ELISA, Beckman
Coulter, Germany) with inter- and intra-assay coefficients of variation of
4 and 6%, respectively. Anti-Müllerian hormone (AMH) was measured by
a paramagnetic particle chemiluminescent immunoassay (Access Beckman
Coulter, Germany) with inter- and intra-assay CV of 4 and 5.8%, respectively.
Genetic analyses
Genomic DNA was purified from whole peripheral blood with the automatic
nucleic acids extractor EZ1 Advanced XL (Qiagen, Hilden, Germany) using
the EZ1 DNA Blood Kit (Qiagen, Hilden, Germany). DNA concentration
was measured with the UV spectrophotometer UV–1601 (Shimadzu,
Milan, Italy). The single nucleotide polymorphisms (SNPs) rs6166
(NM_000145.3:c.2039G.A, NP_000136.2:p.S680N) and rs10835638
(NG_008144.1: g.4790G.T) were genotyped with the high-resolution
melting technology, on a CFX96 Real-Time PCR detection system
(Bio-Rad, Laboratories, Hercules, CA, USA), using the Eva Green Supermix
(Bio-Rad), according to the manufacturers’ protocol. This system is subject to
regular annual checks and calibrations and quality reports are released, in ac-
cordance with the lab accreditation program of the region Emilia Romagna
(http://www.cgr.unimore.it/cgi-bin/cgr/gruppi.pl/View?doc=endolab.html).
Primers used to genotype rs6166 and rs10835638 (328-FSHR-Fw
5′-AACACCCATCCAAGGAAT-3′, 329-FSHR-Rev 5′-ATGACTTAGAG
GGACAAG-3′638-Fw and 638-FSHB-FW 5′-GGTGTGCTACTGTATC
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were designed with the software Beacon Designer 7 (Bio-Rad). A number
(10%) of samples, randomly chosen, were further confirmed through
direct sequencing on a 4-capillary ABI-Prism 3130 Genetic Analyzer instru-
ment (Applied Biosystems, Foster City, CA, USA).
Sperm DFI analyses
Sperm DNA fragmentation was determined by the TUNEL/PI method
(Muratori et al., 2008, 2010). Briefly, after steps of washing, fixation (4% par-
aformaldehyde for 30 min at room temperature) and permeabilization (0.1%
sodium citrate/0.1% Triton X-100, 4 min in ice) samples were labeled
for TUNEL using the ‘In Situ Cell Death Detection Kit, fluorescein’ (Roche
Molecular Biochemicals, Milan, Italy). Samples were shipped in the dark at
48C to the Laboratory of Andrology of the University of Florence within
7 days from collection (Muratori et al., 2010). This protocol allows the deter-
mination of the percentage of DNA fragmented spermatozoa in neat semen
eliminating all the interference present, such as leucocytes, immature germ
cells and apoptotic bodies (Muratori et al., 2008, 2010). At the same time,
this method quantifies DNA fragmentation in two separate cytometric popu-
lations of spermatozoa, dimmer DFI and brighter DFI spermatozoa, charac-
terized by different extents of DNA fragmentation as well as different
associations with semen parameters (Muratori et al., 2015a,b). In addition,
the amount of apoptotic bodies (Marchiani et al., 2007) was evaluated in
all samples (Lotti et al., 2012; Tamburrino et al., 2012).
Statistical analysis
Statistical analysis was performed using the Statistical Package for the Social
Sciences software for Macintosh (version 21.0; SPSS, Inc., Chicago, IL,
USA) through the ‘intention-to-treat’ method (Hollis and Campbell, 1999).
Patients were first divided according to the genotype of the rs6166 in the
FSHR, forming two groups: homozygous FSHR p.N680S N and homozygous
FSHR p.N680S N men, respectively. In addition, patients were stratified
considering the FSHR p.N680S polymorphism together with sperm param-
eter classification. Furthermore, considering the effects of FSHB -211G.T
SNP on serum FSH action (Grigorova et al., 2008) which were described in
detail only after this study began (Grigorova et al., 2010, 2011; Tuttelmann
et al., 2012), patients were further stratified according to the FSHR
p.N680S polymorphism together with FSHB -211G.T SNP.
The distribution of each variable was evaluated through the Kolmogorov–
Smirnov test. The prevalence of patients in each subgroup was compared by
Fisher–Yates test.
Comparison of variables among different groups was performed by uni-
variate analysis of variance when they showed a normal distribution,
whereas Mann–Whitney or Kruskal–Wallis tests were applied for not nor-
mally distributed parameters. Post hoc tests were performed by Dunnet test.
Parameters were compared through Spearman’s correlation coefficient.
For all comparisons, P , 0.05 was considered statistically significant. The
statistical power of the study, considering the primary end-point variation,
was 0.87, with an a error ¼ 0.05.
Results
Of the 163 patients screened, 89 were enrolled, 66 Caucasian men com-
pleted the first analysis (38 p.N680S N homozygous and 28 p.N680S S
homozygous, respectively) and 55 completed the study (Fig. 1).
Median age of the 55 patients who completed the study was 37.0 years
(interquartile range: 25% 33.5; 50% 37.0; 75% 39.0 years; min 26.0; max
48.0 years). A total of 11 drop-outs were registered during the study, 5
from the p.N680S N homozygous group and 6 from the p.N680S S homo-
zygous group (Fig. 1). No drug-related adverse events were registered and
dropping out was entirely the patient’s decision.
No significant differences were found at Visit 1 (baseline) between the
two groups in hormonal and semen parameters analyzed (Table I). In
Figure1 Flow chart of the trial to investigate if treatment of idiopathic infertile men with FSH improves sperm DNA fragmentation, and if this is dependent
on FSH receptor (FSHR) polymorphism.
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Table I Variables at each study visit, dividing idiopathic infertile men according to FSH receptor (FSHR) p.N680S
polymorphism.
Visit 1 Visit 2 Visit 3 P-Value
Total testosterone (ng/ml)
p.N680S S homozygous 5.48+2.16 5.52+2.16 5.79+2.30 0.779
p.N680S N homozygous 5.40+1.61 5.68+2.03 5.69+1.87 0.833
Estradiol (pg/ml)
p.N680S S homozygous 32.96+9.26 32.60+9.44 31.95+8.78 0.926
p.N680S N homozygous 33.26+8.65 29.68+5.92 30.90+7.05 0.275
FSH (IU/l)
p.N680S S homozygous 3.55+1.53 5.08+2.34 3.63+1.42 0.018
p.N680S N homozygous 3.43+1.70 4.08+1.82 3.24+1.48 0.120
LH (IU/l)
p.N680S S homozygous 2.74+1.02 2.88+1.09 2.84+1.26 0.811
p.N680S N homozygous 2.89+1.08 2.76+1.14 3.00+1.19 0.831
AMH (ng/ml)
p.N680S S homozygous 6.62+3.72 7.62+3.99 6.65+4.01 0.361
p.N680S N homozygous 5.50+3.19 5.84+3.42 5.09+2.63 0.767
Inhibin B (pg/ml)
p.N680S S homozygous 160.81+53.05 176.80+60.93 181.16+66.66 0.475
p.N680S N homozygous 194.49+76.27 214.18+119.65 210.63+108.89 0.943
Total DFI (%)
p.N680S S homozygous 57.79+17.70 58.59+19.70 62.11+21.64 0.817
p.N680S N homozygous 57.92+16.98 47.28+16.72 43.68+11.99 0.013
Brighter DFI (%)
p.N680S S homozygous 28.93+12.24 32.18+14–09 24.61+13.23 0.269
p.N680S N homozygous 34.19+15.46 25.48+10.58 22.42+9.34 0.004
Dimmer DFI (%)
p.N680S S homozygous 28.64+13.64 26.59+11.85 37.44+19.90 0.221
p.N680S N homozygous 23.77+11.25 22.87+13.91 21.61+9.18 0.891
Apoptotic bodies (%)
p.N680S S homozygous 34.17+22.74 33.61+22.93 31.67+23.18 0.970
p.N680S N homozygous 26.54+16.98 26.61+21.61 29.21+23.17 0.831
Testicular volume (ml)
p.N680S S homozygous 31.53+10.12 32.36+10.66 32.19+11.09 0.908
p.N680S N homozygous 31.65+9.96 33.88+11.12 31.11+9.92 0.695
Total spermatozoa number (million)
p.N680S S homozygous 80.10+68.98 72.84+84.10 93.62+92.81 0.351
p.N680S N homozygous 84.71+133.93 75.33+109.76 83.82+104.63 0.993
Concentration of spermatozoa (million/ml)
p.N680S S homozygous 24.64+20.10 20.76+21.00 25.53+23.04 0.345
p.N680S N homozygous 24.64+27.90 21.85+26.56 25.32+29.97 0.975
Progressive motility (million)
p.N680S S homozygous 18.49+22.23 13.88+23.42 18.28+25.50 0.218
p.N680S N homozygous 30.30+64.72 17.73+26.00 16.35+21.58 0.903
Non progressive motility (million)
p.N680S S homozygous 9.68+11.25 10.76+14.63 13.00+16.34 0.656
p.N680S N homozygous 12.04+24.23 10.08+18.03 8.50+10.45 0.982
Variables are expressed as mean+ SD. The P values indicate the statistical difference among the three visits through Kruskal–Wallis test. Bold/italic values show significant results.
Visit 1: baseline. Visit 2: after 3 months of FSH treatment. Visit 3: follow-up, 3 months after stopping FSH treatment.
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particular, serum FSH levels, sperm concentration/number and sperm
DFI did not differ between the two groups (Table I). Since inclusion cri-
teria were independent of these parameters, sperm concentration/
number was highly heterogeneous and both groups included men
ranging from severe oligozoospermia to normozoospermia.
FSH administration resulted in a limited increase in serum FSH as mea-
sured at the end of the treatment phase (Visit 2). Serum FSH significantly
differed from baseline only in the p.N680S S homozygous group (Table I).
This reflects the fact that the patients were not requested to come to
Visit 2 immediately after the last injection. The significant increase of
serum FSH levels at Visit 2 in one group and the improvement in DFI
as a treatment effect; however, suggests a good compliance to the
therapy. None of the other hormones (LH, testosterone, estradiol,
inhibin B and AMH) and semen parameters changed among the visits
(Table I).
Twelve pregnancies (both spontaneous and after ART), biochemically
evaluated by serum hCG measurement (higher than 10 mIU/ml), were
observed during and after conclusion of the trial, six (21.4%) in the
p.N680S S homozygous and six (15.8%) in the p.N680S N homozygous
group, without significant differences (P ¼ 0.792).
As expected, DFI values in the three sperm fractions at Visit 1 were
much higher compared with those found in a cohort of fertile men
where DFI was evaluated with the same method (Muratori et al.,
2015a). Total DFI decreased progressively and significantly from visit 1
(57.92+ 16.98%) to Visit 3 (43.68+ 11.99%) only in the p.N680S N
homozygous group (P ¼ 0.013) (Table I). The decrease of total DFI in
FSHR p.N680S N homozygous men was entirely due to a significant de-
crease in the brighter sperm DFI fraction from visit 1 (34.19+ 15.46%)
to visit 3 (22.42+9.34%, P ¼ 0.004) (Table I) (Fig. 2), while the dimmer
and bodies fractions, represented essentially by dead sperm and apop-
totic bodies, respectively, did not change (Table I).
A significant correlation between sperm total DFI and serum testos-
terone levels was observed only in the p.N680S N homozygous men
and only at Visit 2 (R ¼ 20.418, P ¼ 0.038) (Fig. 3). No other significant
correlations were demonstrated among all other parameters (data not
shown). In particular, no significant correlation was found between DFI
values at Visit 1 in the three sperm fractions and patient age (data not
shown), in contrast with previous results (Wyrobek et al., 2006; Lotti
et al., 2012). Lack of correlation with age might be due to the lower
number of subjects and the different age range of the present study.
Since we included both oligozoospermic and normozoospermic men,
we analyzed whether the effect on the sperm DFI was related to sperm
concentration rather than FSHR genotype. Patients were stratified as
normo- (41 patients, 62.12%) and oligozoospermic (25 patients,
37.88%), according to baseline sperm number. The distribution of
oligo- and normozoospermic was not significantly different between
p.N680S N homozygous and p.N680S S homozygous men (P ¼
0.060). The beneficial FSH effect was confirmed only in the p.N680S
N homozygous group (Fig. 4). In particular at Visit 3 brighter DFI
decreased significantly in the p.N680S N homozygous, normozoosper-
mic patients (P ¼ 0.040) (Fig. 4A) and sperm total DFI decreased signifi-
cantly in the p.N680S N homozygous, oligozoospermic men (P ¼ 0.035)
(Fig. 4B). No significant changes were observed in the p.N680S S homo-
zygous patients, confirming that the improvement of sperm DNA frag-
mentation was mainly related to the genotype.
In the literature, several cohort studies demonstrated the relationship
between FSH action and the -211G.T polymorphism in the FSHB gene
(Grigorova et al., 2008, 2010, 2011; Tuttelmann et al., 2012), most of
which were published after this trial was initiated. We, therefore, also
investigated whether the observed FSH effect could be influenced by
this SNP. We found 49 (75.7%) FSHB -211G.T homozygous G patients,
14 (21.2%) FSHB -211G.T heterozygous G/T patients and 2 (3.1%)
FSHB -211G.T homozygous T patients. In one patient the evaluation
Figure 2 Sperm DNA fragmentation index (DFI) changes during the
trial. Results are shown as median (black line), 25th and 75th percentiles
(box plot) and confidence interval (bars). The P value shows the result of
a post hoc test (Dunnet test). Visit 1: baseline. Visit 2: after 3 months of
FSH treatment. Visit 3: follow-up, 3 months after stopping FSH treat-
ment. p.N680S N homozygous: 38 patients; p.N680S S homozygous:
28 patients. (A) Total DFI and (B) brighter DFI.
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of FSHB -211G.T genotype was not possible. Patients were stratified in
four groups according to the FSHR p.N680S and FSHB -211G.T geno-
type, the latter considering the homozygous T and the heterozygous
G/T genotypes together (dominant model). A significant improvement
in sperm total and brighter DFI was found only in carriers of the combin-
ation of FSHR p.N680S N homozygous and FSHB G homozygous geno-
types (Fig. 5). Considering the FSHB -211G.T genotype alone,
irrespective of the FSHR p.N680S genotype, brighter DFI was not differ-
ent between FSHB -211G.T homozygous G (n ¼ 50) and FSHB
-211G.T homozygous T and heterozygous G/T genotypes together
(n ¼ 16). However, brighter DFI decreased significantly among visits
only in the homozygous G group (P ¼ 0.018). A post hoc test showed
significantly lower levels at Visit 3 than Visit 1 (data not shown).
Taken together, these results demonstrate that FSH, at the dose and
duration treatment employed, improves sperm DFI, particularly in the
fraction containing viable spermatozoa, in patients who are carriers of
the FSHR p.N680S N homozygous genotype. This effect is independent
of sperm concentration/number and may be modulated by the FSHB
-211G.T genotype.
Discussion
This study demonstrates that FSH administration to men with idiopathic
infertility improves sperm quality, reducing, with the regimen used,
sperm DNA fragmentation only in FSHR p.N680S N homozygous
men, thereby identifying the FSHR genotype as a putative pharmacoge-
netic marker of FSH response in men. This finding is fully in line with
our previous results obtained in women (Behre et al., 2005) and with
the concept that the FSHR p.N680S N homozygous genotype is more
sensitive to FSH both in vivoand in vitro (Simoni and Casarini, 2013; Casar-
ini et al., 2014). The only other pharmacogenetic study published so far
investigated standard semen parameters in idiopathic, oligozoospermic
men and suggested that not FSHR p.N680S homozygous N men but
rather p.N680S homozygous S men responded to FSH treatment by im-
proving sperm concentration and total sperm number (Selice et al.,
2011). Different patient selection criteria, study design and the well-
known inter-laboratory variability in results of semen analysis (Cooper
et al., 1999; Mallidis et al., 2012) could explain these conflicting results.
Our results, obtained with a rigorous study design, can be fully explained
by the current knowledge of pathophysiology of FSHR polymorphisms
(Simoni and Casarini, 2013).
Figure 4 Sperm DFI changes during the trial in the patients stratified
according to FSHR p.N680S polymorphism and sperm number (normo-
zoospermia and oligozoospermia). Results are shown as median (black
line), 25th and 75th percentiles (box plot) and confidence interval
(bars). The P-value shows the result of a post hoc test (Dunnet test).
Visit 1:baseline.Visit 2: after3 months of FSH treatment. Visit 3: follow-up,
3 monthsafter stopping FSH treatment. (A) Brighter DFI and (B) total DFI.
Figure 3 Spearman’s correlation between total testosterone serum
levels and total DFI. The dataare for FSHR p-N680S N homozygous men
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Sperm DFI represents a promising new diagnostic tool in infertile men,
considering that high sperm DFI levels are associated with poor ART out-
comes (Tamburrino et al., 2012). In addition, sperm DFI appears to be
the most stable, among the other seminal parameters, within the time
of a spermatogenetic cycle (Muratori et al., 2015a). Here, we find that
only the subgroup of FSHR p.N680S homozygous N men experience
an improvement of sperm DFI with FSH treatment. Thus, FSHR
p.N680S could be a predictive marker to recognize which men could
respond better to FSH treatment. Remarkably, this beneficial effect is
not evident immediately after the treatment phase but becomes signifi-
cant after 6 months from study start, a period including 3 months of
FSH administration and 3 months of treatment washout. This suggests
that FSH acts probably at the early steps of spermatogenesis, improving
sperm quality progressively. Thus, the treatment duration chosen might
be too short to be effective in all men. We speculate that FSH adminis-
tration, acting at the early germ cell stage of spermatogenesis, should
cover at least two spermatogenetic cycles in order to produce sperm im-
provement in the majority of men, possibly extending its beneficial effects
to FSHR p.N680S S carriers. Therefore, future studies should consider
extending the FSH treatment phase to at least 6 months.
Sperm DNA fragmentation originates mostly in the testis resulting
from an abortive apoptotic mechanism or from oxidative stress during
transit in the male genital tract (Muratori et al., 2015b). Since FSH is a
germ cell pro-survival factor, altering the ratio of B-cell lymphoma 2
(BCl2) family protein members (Ruwanpura et al., 2008a,b), we specu-
late that FSH decreases sperm DFI by reducing apoptosis in the testis.
Stratifying the patients according to sperm concentration/number did
not change the result that only FSHR p.N680S N homozygous men
respond with an improvement of sperm DFI. Although the number of
men studied is low, it seems that FSHR p.N680S N homozygosis/high
basal levels of DFI is a better predictor of response to FSH treatment
than basal semen parameters.
The other patient stratification applied, according to the FSHB
-211G.T polymorphism, confirmed the positive effect only in FSHR
p.N680S N homozygous men and, in addition, identified the FSHB
-211G.T G homozygous genotype as the most responsive to FSH
therapy. This result seems to be in contrast to the only previous study
available in the literature (Ferlin et al., 2011). However, although the
FSHB -211G.T analysis was applied a posteriori, and a selection bias
exists, since only homozygous FSHR p.N680S were included in the
study, this result is in line with the model proposed by Tuttelmann
et al. (2012). In this cohort study, the authors proposed a ‘traffic light’
model in which FSHR p.N680S and FSHB -211G.T SNPs interacted in-
fluencing FSH action (Tuttelmann et al., 2012). Tuttelmann et al. pro-
posed that those men with the genotype combination FSHR
2039A.G AA or AG and FSHB -211G.T GG (in the ‘green’ area of
the model in Fig. 2 in Tuttelmann et al., 2012) were carriers of the best
combination for FSH action. In our study, patients with such genotype
combination, corresponding to the ‘green’ area, are indeed the best
responders to FSH, probably due to a more favorable genetic back-
ground of higher FSHR sensitivity and higher exposure to endogenous
FSH. Considering the two polymorphisms together, total and brighter
DFI improved in combined FSHR p.N680S N homozygous and FSHB
-211G.T G homozygous men. However, a larger sample size is
needed to better understand the influence and the interaction of these
two SNPs on the response to FSH treatment in men. Future studies
should prospectively evaluate the effects of FSH in men stratified accord-
ing to both genotypes and based on more personalized treatment regi-
mens, i.e. longer treatment duration with higher FSH doses in men
with less responsive FSHR/FSHB genotype combinations, possibly asses-
sing ART outcome and/or spontaneous pregnancies.
We recently demonstrated the molecular basis for the different re-
sponse to FSH of the two FSHR p.N680S genotypes in human granulosa-
lutein cells (hGLC) (Casarini et al., 2014). In vitro, upon stimulation with
recombinant FSH, FSHR p.N680S homozygous N hGLC show a faster
Figure 5 Changes in sperm DFI during the trial. Patients were stratified
according to FSHR p.N680S polymorphism and FSHB -211G.T poly-
morphism (GG versus GT and TT. Results are shown as median (black
line), 25th and 75th percentiles (box plot) and confidence interval (bars).
The P-value shows the result of a post hoc test (Dunnet test). Visit 1: base-
line; Visit 2: after 3 months of FSH treatment; Visit 3: follow-up, 3 months
after stopping FSH treatment. (A) Total DFI and (B) brighter DFI.
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cyclic adenosine mono-phosphate (cAMP) and progesterone produc-
tion rate and a higher phosphorylated extracellular signal-regulated
kinase 1/2 and cAMP response element-binding protein CREB phos-
phorylation compared with the homozygous FSHR p.N680S S hGLC
(Casarini et al., 2014). Therefore, the present results are completely con-
sistent with the expected higher sensitivity of the FSHR p.N680S N geno-
type both in vivo and in vitro (Casarini et al., 2014; Simoni and Casarini,
2014).
Finally, we confirm that FSH treatment does not affect the hormonal
status. In particular, no significant modifications were found in serum
AMH, inhibin B, testosterone, estradiol and gonadotrophin levels.
However, a significant and inverse relationship is found between total
testosterone serum levels and sperm DFI only in FSHR p.N680S N
homozygous men at the end of treatment phase. This result suggests a
possible effect of FSH administration on testosterone in a specific sub-
group of infertile men, mediated by FSH sensitivity. However, the low
number of patients enrolled to this arm suggests caution in interpret-
ation.
In conclusion, we demonstrate that FSH administration to infertile
men is effective in reducing sperm DNA fragmentation when the FSHR
p.N680S polymorphism is considered in selecting patients. In particular,
the FSH regimen applied improves sperm quality when FSHR p.N680S N
homozygosis is present. The effect is seen both in normo- and in oligo-
zoospermic men and is associated with the FSHB -211G/T polymorph-
ism. The relatively low number of subjects represents a limitation of this
study but the rigorous design suggests that the highest beneficial effect of
FSH is obtained in men carrying the combined FSHR p.N680S N homo-
zygous and FSHB -211G/T G homozygous genotypes.
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